Iscover

Clopidogrel, the active ingredient in Iscover, is an antiplatelet agent presented as an oral tablet for oral use. It is indicated to reduce the risk of clot‑related events such as heart attack, stroke and peripheral arterial disease in patients with established cardiovascular disease. It works by irreversibly blocking platelet activation, providing long‑lasting protection against thrombus formation.

GNH USA supplies Iscover as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements.

Clopidogrel is used to prevent thrombotic cardiovascular events by inhibiting platelet aggregation in several clinical settings.

Prevention of atherothrombotic events: reduces recurrence of myocardial infarction, ischemic stroke and peripheral arterial disease complications in patients with prior events. Acute coronary syndrome: helps limit further clot formation during unstable angina or myocardial infarction, supporting early medical management. Post‑percutaneous coronary intervention: lowers the risk of stent thrombosis after PCI, contributing to long‑term vessel patency.

Clopidogrel may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Bleeding gums or easy bruising - Nausea or abdominal discomfort - Headache or dizziness - Diarrhea

Serious or Rare Side Effects: - Severe or uncontrolled bleeding, including intracranial hemorrhage - Thrombotic thrombocytopenic purpura (TTP) - Allergic reactions such as rash, pruritus or angioedema

When prescribing clopidogrel, clinicians should consider several precautionary measures to ensure safe use. - Assess bleeding risk: evaluate history of gastrointestinal ulcers, hemorrhagic disorders or recent surgery. - Monitor platelet function: periodic laboratory testing may be needed in patients with unexplained bleeding. - Avoid concomitant use with other antiplatelet or anticoagulant agents unless clinically justified. - Renal or hepatic impairment: dose adjustment may be required based on physician assessment. - Pregnancy and lactation: use only if potential benefit outweighs potential risk to fetus or infant. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Clopidogrel can interact with several medicines, altering its antiplatelet activity or increasing bleeding risk.

Major Interactions (Avoid): - Strong CYP2C19 inhibitors (e.g., omeprazole, fluconazole): may reduce conversion to active metabolite, decreasing efficacy. - Concurrent use of oral anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increases bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) at high doses: potentiate gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors with weaker CYP2C19 inhibition (e.g., pantoprazole): may modestly affect activation. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: can increase bleeding tendency. - Statins metabolized by CYP3A4 (e.g., atorvastatin): potential for modest pharmacokinetic interaction.